UMMS Affiliation

Department of Medicine, Division of Endocrinology and Metabolism

Publication Date


Document Type

Letter to the Editor


Cardiovascular Diseases | Endocrine System Diseases | Endocrinology, Diabetes, and Metabolism | Nutritional and Metabolic Diseases


SGLT2 inhibitor (SGLT2i) class of medications are known to cause to euglycemic diabetic ketoacidosis (euDKA) as reported in the article by Lin et al. in your esteemed publication about this entity being reported for the first time in Taiwanese population.We wish to share the findings from our center to further expand the spectrum of findings associated with SGLT2i therapy.


Cardiovascular, Euglycemic-diabetic ketoacidosis, Ketonemia, SGLT2

Rights and Permissions

Copyright 2019, Formosan Medical Association. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (

DOI of Published Version



J Formos Med Assoc. 2019 May 14. pii: S0929-6646(19)30390-0. doi: 10.1016/j.jfma.2019.04.021. [Epub ahead of print] Link to article on publisher's site

Journal/Book/Conference Title

Journal of the Formosan Medical Association = Taiwan yi zhi

Related Resources

Link to Article in PubMed

PubMed ID


Creative Commons License

Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.